These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 15854239)

  • 1. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.
    Xu M; See SJ; Ng WH; Arul E; Back MF; Yeo TT; Lim CC
    Neurosurgery; 2005 May; 56(5):919-26; discussion 919-26. PubMed ID: 15854239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.
    Spampinato MV; Smith JK; Kwock L; Ewend M; Grimme JD; Camacho DL; Castillo M
    AJR Am J Roentgenol; 2007 Jan; 188(1):204-12. PubMed ID: 17179366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.
    Law M; Oh S; Johnson G; Babb JS; Zagzag D; Golfinos J; Kelly PJ
    Neurosurgery; 2006 Jun; 58(6):1099-107; discussion 1099-107. PubMed ID: 16723889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values.
    Senft C; Hattingen E; Pilatus U; Franz K; Schänzer A; Lanfermann H; Seifert V; Gasser T
    Neurosurgery; 2009 Nov; 65(5):908-13; discussion 913. PubMed ID: 19834403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast/Noise ratio on conventional MRI and choline/creatine ratio on proton MRI spectroscopy accurately discriminate low-grade from high-grade cerebral gliomas.
    Fayed N; Morales H; Modrego PJ; Pina MA
    Acad Radiol; 2006 Jun; 13(6):728-37. PubMed ID: 16679275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
    Fayed N; Dávila J; Medrano J; Olmos S
    Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
    Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors.
    Astrakas LG; Zurakowski D; Tzika AA; Zarifi MK; Anthony DC; De Girolami U; Tarbell NJ; Black PM
    Clin Cancer Res; 2004 Dec; 10(24):8220-8. PubMed ID: 15623597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
    Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
    NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
    Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
    Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy.
    Oshiro S; Tsugu H; Komatsu F; Abe H; Onishi H; Ohmura T; Iwaasa M; Sakamoto S; Fukushima T
    Anticancer Res; 2007; 27(6A):3757-63. PubMed ID: 17970039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
    Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
    Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting survival of children with CNS tumors using proton magnetic resonance spectroscopic imaging biomarkers.
    Marcus KJ; Astrakas LG; Zurakowski D; Zarifi MK; Mintzopoulos D; Poussaint TY; Anthony DC; De Girolami U; Black PM; Tarbell NJ; Tzika AA
    Int J Oncol; 2007 Mar; 30(3):651-7. PubMed ID: 17273766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation.
    Toyooka M; Kimura H; Uematsu H; Kawamura Y; Takeuchi H; Itoh H
    Clin Imaging; 2008; 32(4):251-8. PubMed ID: 18603178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors.
    Sankar T; Moore NZ; Johnson J; Ashby LS; Scheck AC; Shapiro WR; Smith KA; Spetzler RF; Preul MC
    J Neurosurg; 2012 Jun; 116(6):1172-81. PubMed ID: 22424566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI.
    Yang D; Korogi Y; Sugahara T; Kitajima M; Shigematsu Y; Liang L; Ushio Y; Takahashi M
    Neuroradiology; 2002 Aug; 44(8):656-66. PubMed ID: 12185543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.
    Di Costanzo A; Trojsi F; Giannatempo GM; Vuolo L; Popolizio T; Catapano D; Bonavita S; d'Angelo VA; Tedeschi G; Scarabino T
    J Exp Clin Cancer Res; 2006 Sep; 25(3):383-90. PubMed ID: 17167979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
    Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
    Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric MR assessment of pediatric brain tumors.
    Tzika AA; Astrakas LG; Zarifi MK; Petridou N; Young-Poussaint T; Goumnerova L; Zurakowski D; Anthony DC; Black PM
    Neuroradiology; 2003 Jan; 45(1):1-10. PubMed ID: 12525947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas.
    Chawla S; Oleaga L; Wang S; Krejza J; Wolf RL; Woo JH; O'Rourke DM; Judy KD; Grady MS; Melhem ER; Poptani H
    J Neuroimaging; 2010 Jan; 20(1):3-8. PubMed ID: 19021846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.